Leaders from Eli Lilly and Vertex Pharmaceuticals, 9amHealth, Features Capital, and accelerator PharmStars discussed the convergence of biopharma, medtech and healthtech, and what is needed to achieve health care transformation, in an LSX World Congress USA panel.

The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.

The Copenhagen-headquartered group is taking its antibody-drug conjugate rinatabart sesutecan into Phase III and chief medical officer Tahi Ahmadi tells Scrip that it has the potential to treat far more women than the only currently marketed FRα-targeting ADC, AbbVie's Elahere.

Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.